Research ExplorerPublicationsClinical Outcomes of SARS-CoV-2 Breakthrough Infections in L...

Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave

Standard

Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. / Herting, Anna; Jahnke-Triankowski, Jacqueline; Harberts, Aenne; Schaub, Golda M; Lütgehetmann, Marc; Ruether, Darius F; Fischer, Lutz; Addo, Marylyn M; Lohse, Ansgar W; Schulze Zur Wiesch, Julian; Sterneck, Martina.

In: VIRUSES-BASEL, Vol. 15, No. 2, 297, 20.01.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Herting, A, Jahnke-Triankowski, J, Harberts, A, Schaub, GM, Lütgehetmann, M, Ruether, DF, Fischer, L, Addo, MM, Lohse, AW, Schulze Zur Wiesch, J & Sterneck, M 2023, 'Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave', VIRUSES-BASEL, vol. 15, no. 2, 297. https://doi.org/10.3390/v15020297

APA

Herting, A., Jahnke-Triankowski, J., Harberts, A., Schaub, G. M., Lütgehetmann, M., Ruether, D. F., Fischer, L., Addo, M. M., Lohse, A. W., Schulze Zur Wiesch, J., & Sterneck, M. (2023). Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. VIRUSES-BASEL, 15(2), [297]. https://doi.org/10.3390/v15020297

Vancouver

Herting A, Jahnke-Triankowski J, Harberts A, Schaub GM, Lütgehetmann M, Ruether DF et al. Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. VIRUSES-BASEL. 2023 Jan 20;15(2). 297. https://doi.org/10.3390/v15020297

Bibtex

@article{becfa52cd8dc4707ba753a780d3d97df,
title = "Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave",
abstract = "At the start of the pandemic, liver transplant recipients (LTR) were at high risk of developing severe COVID-19. Here, the outcomes of breakthrough infections in fully vaccinated LTR (n = 98) during the Omicron wave were assessed. In most patients, a mild disease course was observed, but 11 LTR (11.2%) required hospitalization for COVID-19-related complications. All patients survived. The LTR requiring hospitalization were older (67 years vs. 54 years; p < 0.001), had a higher Charlson comorbidity index (9 vs. 5; p < 0.001), and a lower anti-S RBD titer (Roche Elecsys) prior to infection (508.3 AU/mL vs. 2044 AU/mL; p = 0.03). Long-lasting symptoms for ≥4 weeks were reported by 37.5% of LTR (30/80). Risk factors in LTR included female sex (p = 0.01; Odds Ratio (OR) = 4.92 (95% confidence interval (CI) (1.5-16.5)) and dyspnea (p = 0.009; OR = 7.2 (95% CI (1.6-31.6)) during infection. Post-infection high anti-S RBD antibody levels were observed in LTR, and healthy controls (HC), while the cellular immune response, assessed by interferon-gamma release assay (EUROIMMUN), was significantly lower in LTR compared with HC (p < 0.001). In summary, in fully vaccinated LTR, SARS-CoV-2 breakthrough infections during the Omicron wave led to mild disease courses in the majority of patients and further boosted the humoral and cellular hybrid anti-SARS-CoV-2-directed immune response. While all patients survived, older and multimorbid LTR with low baseline antibody titers after vaccination still had a substantial risk for a disease course requiring hospitalization due to COVID-19-related complications.",
keywords = "Humans, Female, COVID-19, Breakthrough Infections, Liver Transplantation/adverse effects, SARS-CoV-2, Antibodies, Disease Progression",
author = "Anna Herting and Jacqueline Jahnke-Triankowski and Aenne Harberts and Schaub, {Golda M} and Marc L{\"u}tgehetmann and Ruether, {Darius F} and Lutz Fischer and Addo, {Marylyn M} and Lohse, {Ansgar W} and {Schulze Zur Wiesch}, Julian and Martina Sterneck",
year = "2023",
month = jan,
day = "20",
doi = "10.3390/v15020297",
language = "English",
volume = "15",
journal = "VIRUSES-BASEL",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave

AU - Herting, Anna

AU - Jahnke-Triankowski, Jacqueline

AU - Harberts, Aenne

AU - Schaub, Golda M

AU - Lütgehetmann, Marc

AU - Ruether, Darius F

AU - Fischer, Lutz

AU - Addo, Marylyn M

AU - Lohse, Ansgar W

AU - Schulze Zur Wiesch, Julian

AU - Sterneck, Martina

PY - 2023/1/20

Y1 - 2023/1/20

N2 - At the start of the pandemic, liver transplant recipients (LTR) were at high risk of developing severe COVID-19. Here, the outcomes of breakthrough infections in fully vaccinated LTR (n = 98) during the Omicron wave were assessed. In most patients, a mild disease course was observed, but 11 LTR (11.2%) required hospitalization for COVID-19-related complications. All patients survived. The LTR requiring hospitalization were older (67 years vs. 54 years; p < 0.001), had a higher Charlson comorbidity index (9 vs. 5; p < 0.001), and a lower anti-S RBD titer (Roche Elecsys) prior to infection (508.3 AU/mL vs. 2044 AU/mL; p = 0.03). Long-lasting symptoms for ≥4 weeks were reported by 37.5% of LTR (30/80). Risk factors in LTR included female sex (p = 0.01; Odds Ratio (OR) = 4.92 (95% confidence interval (CI) (1.5-16.5)) and dyspnea (p = 0.009; OR = 7.2 (95% CI (1.6-31.6)) during infection. Post-infection high anti-S RBD antibody levels were observed in LTR, and healthy controls (HC), while the cellular immune response, assessed by interferon-gamma release assay (EUROIMMUN), was significantly lower in LTR compared with HC (p < 0.001). In summary, in fully vaccinated LTR, SARS-CoV-2 breakthrough infections during the Omicron wave led to mild disease courses in the majority of patients and further boosted the humoral and cellular hybrid anti-SARS-CoV-2-directed immune response. While all patients survived, older and multimorbid LTR with low baseline antibody titers after vaccination still had a substantial risk for a disease course requiring hospitalization due to COVID-19-related complications.

AB - At the start of the pandemic, liver transplant recipients (LTR) were at high risk of developing severe COVID-19. Here, the outcomes of breakthrough infections in fully vaccinated LTR (n = 98) during the Omicron wave were assessed. In most patients, a mild disease course was observed, but 11 LTR (11.2%) required hospitalization for COVID-19-related complications. All patients survived. The LTR requiring hospitalization were older (67 years vs. 54 years; p < 0.001), had a higher Charlson comorbidity index (9 vs. 5; p < 0.001), and a lower anti-S RBD titer (Roche Elecsys) prior to infection (508.3 AU/mL vs. 2044 AU/mL; p = 0.03). Long-lasting symptoms for ≥4 weeks were reported by 37.5% of LTR (30/80). Risk factors in LTR included female sex (p = 0.01; Odds Ratio (OR) = 4.92 (95% confidence interval (CI) (1.5-16.5)) and dyspnea (p = 0.009; OR = 7.2 (95% CI (1.6-31.6)) during infection. Post-infection high anti-S RBD antibody levels were observed in LTR, and healthy controls (HC), while the cellular immune response, assessed by interferon-gamma release assay (EUROIMMUN), was significantly lower in LTR compared with HC (p < 0.001). In summary, in fully vaccinated LTR, SARS-CoV-2 breakthrough infections during the Omicron wave led to mild disease courses in the majority of patients and further boosted the humoral and cellular hybrid anti-SARS-CoV-2-directed immune response. While all patients survived, older and multimorbid LTR with low baseline antibody titers after vaccination still had a substantial risk for a disease course requiring hospitalization due to COVID-19-related complications.

KW - Humans

KW - Female

KW - COVID-19

KW - Breakthrough Infections

KW - Liver Transplantation/adverse effects

KW - SARS-CoV-2

KW - Antibodies

KW - Disease Progression

U2 - 10.3390/v15020297

DO - 10.3390/v15020297

M3 - SCORING: Journal article

C2 - 36851510

VL - 15

JO - VIRUSES-BASEL

JF - VIRUSES-BASEL

SN - 1999-4915

IS - 2

M1 - 297

ER -